Close

Evotec, Roche collaborate to develop oncology biomarkers

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Evotec has entered into an oncology research and development agreement with Roche to organize multiple protein-activity based biomarker programs for Roche’s therapeutic antibodies or small molecule inhibitors under development.

Under the agreement, Evotec will use PhosphoScout platform for discovery of protein-phosphorylation’s that predict favorable dosage and efficacy of targeted cancer drugs in patients.

Evotec’s PhosphoScout platform uses mass spectrometry for identifying and quantifying thousands of cellular phosphorylation events on a global scale.

However, Roche expects to conduct clinical trials and will evaluate the development of companion diagnostics for patient stratification.

The tie up allows Evotec to get an undisclosed up-front and success-based payments from Roche for each program.

Roche Pharma Research and Exploratory Development Oncology global head Mike Burgess said they are pleased to collaborate with Evotec and benefit from the PhosphoScout technology to identify appropriate pharmacodynamics and patient stratification biomarkers.

“These biomarkers are core to the development of targeted therapeutics for cancer therapy,” Burgess said.

Latest stories

Related stories

Biopharma Production with AI: A New Era in Manufacturing

A New Era of Biopharma Production with AI The biopharma...

AI Drug Discovery Transforming APAC Biopharma Innovation

The Asia-Pacific (APAC) biopharmaceutical space is being revolutionized by...

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back